Cargando…
Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models is...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029724/ https://www.ncbi.nlm.nih.gov/pubmed/32073727 http://dx.doi.org/10.15252/msb.20188664 |
_version_ | 1783499226506854400 |
---|---|
author | Eduati, Federica Jaaks, Patricia Wappler, Jessica Cramer, Thorsten Merten, Christoph A Garnett, Mathew J Saez‐Rodriguez, Julio |
author_facet | Eduati, Federica Jaaks, Patricia Wappler, Jessica Cramer, Thorsten Merten, Christoph A Garnett, Mathew J Saez‐Rodriguez, Julio |
author_sort | Eduati, Federica |
collection | PubMed |
description | Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models is the limited material available that precludes the generation of large‐scale perturbation data. Here, we present an approach that couples ex vivo high‐throughput screenings of cancer biopsies using microfluidics with logic‐based modeling to generate patient‐specific dynamic models of extrinsic and intrinsic apoptosis signaling pathways. We used the resulting models to investigate heterogeneity in pancreatic cancer patients, showing dissimilarities especially in the PI3K‐Akt pathway. Variation in model parameters reflected well the different tumor stages. Finally, we used our dynamic models to efficaciously predict new personalized combinatorial treatments. Our results suggest that our combination of microfluidic experiments and mathematical model can be a novel tool toward cancer precision medicine. |
format | Online Article Text |
id | pubmed-7029724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70297242020-02-25 Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies Eduati, Federica Jaaks, Patricia Wappler, Jessica Cramer, Thorsten Merten, Christoph A Garnett, Mathew J Saez‐Rodriguez, Julio Mol Syst Biol Articles Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models is the limited material available that precludes the generation of large‐scale perturbation data. Here, we present an approach that couples ex vivo high‐throughput screenings of cancer biopsies using microfluidics with logic‐based modeling to generate patient‐specific dynamic models of extrinsic and intrinsic apoptosis signaling pathways. We used the resulting models to investigate heterogeneity in pancreatic cancer patients, showing dissimilarities especially in the PI3K‐Akt pathway. Variation in model parameters reflected well the different tumor stages. Finally, we used our dynamic models to efficaciously predict new personalized combinatorial treatments. Our results suggest that our combination of microfluidic experiments and mathematical model can be a novel tool toward cancer precision medicine. John Wiley and Sons Inc. 2020-02-19 /pmc/articles/PMC7029724/ /pubmed/32073727 http://dx.doi.org/10.15252/msb.20188664 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Eduati, Federica Jaaks, Patricia Wappler, Jessica Cramer, Thorsten Merten, Christoph A Garnett, Mathew J Saez‐Rodriguez, Julio Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
title | Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
title_full | Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
title_fullStr | Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
title_full_unstemmed | Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
title_short | Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
title_sort | patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029724/ https://www.ncbi.nlm.nih.gov/pubmed/32073727 http://dx.doi.org/10.15252/msb.20188664 |
work_keys_str_mv | AT eduatifederica patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies AT jaakspatricia patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies AT wapplerjessica patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies AT cramerthorsten patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies AT mertenchristopha patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies AT garnettmathewj patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies AT saezrodriguezjulio patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies |